Orka (NASDAQ: ORKA) Stock Soars on Positive Trial Results and Analyst Upgrade

Font: Financial Modeling Prep  • Apr 27, 2026

• Analyst Confidence: Barclays (NYSE: BCS) restated an "Overweight" rating and significantly raised its price target for Orka, signaling strong investor confidence in the biotechnology stock.
• Strong Trial Data: Positive Phase 2a clinical trial results for Orka's drug candidate ORKA-001 showed a remarkable 63.5% PASI 100 score in patients with moderate-to-severe plaque psoriasis.
• Market Reaction: The positive news led to an 18.93% surge in Orka's stock price, reaching a new 52-week high and reflecting robust market performance.

Orka (NASDAQ: ORKA) is a clinical-stage biotechnology company with a market capitalization of approximately $3.07 billion. The company focuses on developing new treatments for medical conditions. Its main drug candidate, ORKA-001, is an antibody designed to treat moderate-to-severe plaque psoriasis, a chronic skin disease that causes itchy, scaly patches.

On April 27, 2026, the investment bank Barclays restated its "Overweight" rating for Orka. An "Overweight" rating means the analyst expects the stock to perform better than the average return of other stocks in its sector. This positive outlook is a key signal for investors about the company's potential.

Alongside the rating, Barclays significantly raised its stock price target for Orka to $160 from a previous target of $78. A price target is an analyst's projection of a stock's future price. At the time of the announcement, the stock was trading at $82.40 per share, showing the analyst's strong confidence in the biotech stock's future.

This confidence stems from positive trial results for the drug ORKA-001. As highlighted by GlobeNewswire, Orka announced that its Phase 2a trial achieved a 63.5% PASI 100 score. This score represents complete skin clearance, which was seen in 40 out of 63 patients in the study.

The news caused the stock price to increase by 18.93% in a single day, reaching a new 52-week high of $91.00. This is a substantial rise from its 52-week low of $8.91. Orka also noted the drug has a favorable safety profile, supporting its potential for future use in plaque psoriasis treatment.